Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function.
Katia KhouryFilipa LynceAna BaracXue GengChau DangAnthony F YuKaren L SmithChristopher GallagherPaula R PohlmannRaquel NunesPia HerbolsheimerRobert WarrenMonvadi B SrichaiMark HofmeyerFederico AschMing TanClaudine IsaacsSandra M SwainPublished in: Breast cancer research and treatment (2021)
Long-term follow-up of the SAFE-HEaRt study continues to provide safety data of HER2-targeted therapy use in patients with compromised heart function. The late development of cardiac dysfunction is uncommon and continued multi-disciplinary oncologic and cardiac care of patients is vital for improved patient outcomes.
Keyphrases
- heart failure
- clinical trial
- left ventricular
- atrial fibrillation
- end stage renal disease
- healthcare
- ejection fraction
- newly diagnosed
- chronic kidney disease
- palliative care
- prognostic factors
- randomized controlled trial
- machine learning
- electronic health record
- study protocol
- big data
- robot assisted
- double blind
- deep learning
- phase iii